Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Inventory (2016 - 2025)

Sanofi's Inventory history spans 11 years, with the latest figure at $11.9 billion for Q4 2025.

  • For Q4 2025, Inventory rose 17.98% year-over-year to $11.9 billion; the TTM value through Dec 2025 reached $11.9 billion, up 17.98%, while the annual FY2025 figure was $11.5 billion, 13.05% up from the prior year.
  • Inventory for Q4 2025 was $11.9 billion at Sanofi, up from $10.1 billion in the prior quarter.
  • Across five years, Inventory topped out at $11.9 billion in Q4 2025 and bottomed at $9.1 billion in Q4 2022.
  • The 5-year median for Inventory is $10.1 billion (2024), against an average of $10.3 billion.
  • The largest annual shift saw Inventory fell 8.31% in 2022 before it rose 17.98% in 2025.
  • A 5-year view of Inventory shows it stood at $10.0 billion in 2021, then dropped by 8.31% to $9.1 billion in 2022, then grew by 13.77% to $10.4 billion in 2023, then decreased by 3.1% to $10.1 billion in 2024, then rose by 17.98% to $11.9 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Inventory are $11.9 billion (Q4 2025), $10.1 billion (Q4 2024), and $10.4 billion (Q4 2023).